Moderna, Inc. (MRNA) stock plummeted 6.26% on Monday during intraday trading, following the company's disappointing international revenue performance in the fourth quarter of 2024.
The biotechnology company reported total revenue of $966 million for the quarter, marking a significant 65.6% decline from the prior-year period. While Moderna's revenue from Europe exceeded expectations, contributing $292 million (30.23% of total revenue), its performance in the rest of world markets fell short of analysts' projections.
Revenue from the rest of world region totaled $397 million (41.10% of total revenue), missing Wall Street estimates by 27.97%. This lackluster performance, coupled with analysts' projections of further revenue declines in 2025, likely contributed to Moderna's stock plunge.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。